Whether you’re sizing the addressable market for a specific disease area or refining your pricing assumptions for a potential new asset, you need analytics that can give you the most precise inputs, fast.
We released a new analytics software, called Clarify Portfolio, to help business development and licensing (BD&L) teams make better investment decisions. It arms you with the input needed to gauge the true value of a potential partnership or market. Like all of our software products, Clarify Portfolio is built on our enterprise platform and its insights draw upon our proprietary patient-level, longitudinal data sets that span over 300M lives of government and commercial claims, lab, prescription, and social determinants data. With Clarify Portfolio, cookie-cutter reports and clunky script data can be a thing of the past. You’ll improve the precision of the assumptions you make on market size, future uptake, and cost of sales with higher-fidelity insights; you’ll be able to get instant answers to your business questions as they arise with our self-serve front-end; and you’ll be able to easily slice and dice data without relying on any customization.
When BD&L teams are armed with Clarify Portfolio, they have the ability to do:
- Market Sizing – How many patients with a disease have a set of specific clinical criteria (i.e., are likely to meet the label)?
- Patient Profiling – What clinical characteristics mark each precision cohort (e.g., unmet need, HC system touchpoints)?
- Market Segmentation – How does the target population break down in terms of geography and demographics, as well as over time?
- HCP Profiling – Which types of HCPs / sites treat these patients? How many are there and where are they located?